ATL 1102

• UNSPSC Description:

  ATL 1102 is a novel second-generation antisense oligonucleotide to CD49d mRNA

• Target Antigen:

  Integrin

• Type:

  Oligonucleotides

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/atl-1102.html

• Solubility:

  10 mM in H2O

• Smiles:

  [ATL 1102]

• References & Citations:

  [1]Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One. 2017;12(11):e0187684. |[2]Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS [published correction appears in Neurology. 2015 Jan 6;84(1):105]. Neurology. 2014;83(20):1780-1788.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  350263-41-1